Disease Spotlight: Prostate Cancer

Carch up on the top radiology content of the past week.

The approval of Blue Earth Diagnostics' Posluma (flotufolastat F 18) is a significant step forward for PSMA PET imaging, but will it actually help improve patient outcomes?

In multiple datasets from a study involving reviewed data from over 2,700 bi-parametric magnetic resonance imaging (MRI) scans, a deep neural network demonstrated area under the receiver operating characteristic (AUROC) scores ranging from 87 to 89 percent for the detection of clinically significant prostate cancer.

Catch up on the top radiology content of the past week.

Combining multimodal imaging data and biopsy data, an artificial intelligence (AI) model provided enhanced sensitivity for defining prostate cancer tumor margins in comparison to conventional magnetic resonance imaging (MRI) assessments.

For patients initially diagnosed with non-metastatic, castration-resistant prostate cancer, pelvic lymph node involvement and five or more polymetastases detected with prostate-specific membrane antigen (PSMA)/ positron emission tomography (PET) are significantly associated with lower overall survival rates, according to recently presented research at the American Society of Clinical Oncology (ASCO) conference.

Catch up on the top radiology content of the past week.

Reportedly the first FDA-approved PSMA PET agent with proprietary radiohybrid technology, POSLUMA can be utilized for positron emission tomography (PET) scans of prostate-specific membrane antigen (PSMA) positive lesions in men with prostate cancer and suspected metastasis, and those with suspected prostate cancer recurrence based on an elevated serum prostate-specific antigen (PSA) level.

Catch up on the top radiology content of the past week.

Catch up on the top AI-related news and research from the past month.

In a multinational, multicenter study of over 1,000 patients with recurrent prostate cancer, researchers developed and validated a nomogram that achieved a 72 percent concordance index for the prediction of biochemical recurrence after PSMA PET-guided salvage radiotherapy.

Catch up on the top radiology content of the past week.

The use of adjunctive artificial intelligence (AI) reportedly improved lesion level sensitivity by nearly 19 percent and patient level specificity by 14 percent for the diagnosis of clinically significant prostate cancer on multiparametric magnetic resonance imaging (MRI).

In a recent video interview from the American Urological Association (AUA) 2023 Annual Meeting, Brian Helfand, M.D., discussed emerging research that shows the potential viability of the agent F18-rhPSMA-7.3 for enhancing the detection of prostate cancer recurrence and facilitating earlier intervention for patients with low prostate-specific antigen (PSA) levels.

An update to Quantib Prostate 2.1, Quantib Prostate 3.0 reportedly facilitates workflow advances and offers a variety of tools, ranging from artificial intelligence (AI)-based segmentation to PI-RADS scoring support, to help improve interpretation of prostate magnetic resonance imaging (MRI).

The FDA granted 510(k) clearance to Unfold AI, which was formerly known as iQuest, in December 2022.

In addition to a previously FDA-cleared brain magnetic resonance imaging (MRI) module, the Advantis Platform features an artificial intelligence-powered prostate MRI module that offers simultaneous viewing of conventional and advanced sequences, and reportedly generates automated PI-RADS assessments.

In a study of over 1,200 men with over 3,200 prostatic lesions, an explainable artificial intelligence (AI) model demonstrated a sensitivity rate of 93 percent for detecting clinically significant prostate cancer.

A new study shows that active surveillance and watchful waiting are being utilized in nearly 60 percent of patients with low-risk prostate cancer in the United States.

Catch up on the top radiology content of the past week.

In a recent study of a deep learning software in patients with suspected prostate cancer, researchers noted no difference in the detection of clinically significant prostate cancer nor PI-RADS scoring consistency.

The expanded indication could facilitate improved access to imaging for patients with metastatic prostate cancer who are candidates for radioligand treatment.

In a video interview from the recent American Society of Clinical Oncology Genitourinary Cancers (ASCO GU) Symposium, Brian Chapin, MD, discussed emerging research that demonstrated the ability of the positron emission tomography (PET) agent 18F-rhPSMA-7.3 to diagnose distant M1 lesions prior to surgery for patients with intermediate to high-risk prostate cancer.

New research from the American Cancer Society comparing pre-pandemic cancer screening prevalence to the second year of the COVID-19 pandemic in the United States showed a 1.1 million decrease in breast cancer screenings, a 4.4 million decrease in cervical cancer screening and a 600,000 decrease in prostate cancer screenings.

Catch up on the top radiology content of the past week.